Re-Thinking ASD Development: When Your Molecule Breaks The Rules

Re-Thinking ASD Development starts with challenging assumptions. In this episode of the AustinPx Live Series, we take a closer look at how KinetiSol™ Technology reshapes the way amorphous solid dispersions are developed, scaled, and commercialized. Rather than treating scale-up as a late-stage hurdle, this session explores how a solvent-free, fusion-based platform enables rapid screening early while maintaining the same operating principle through clinical and commercial manufacturing. We discuss how KinetiSol expands formulation design space, supports higher-performing dispersions, and reduces operational complexity compared to conventional approaches. The focus is not just on bioavailability enhancement, but on building programs that align performance with scalability and sustainability from the start. By integrating development strategy with real-world manufacturability, this episode highlights why more teams are evaluating KinetiSol earlier in their programs. Scalable. Sustainable. Performance. Learn more at www.austinpx.com/kinetisol.